Navigation Links
Advancements in Population Age and Technology Drive Future of Orthopedic Materials Market
Date:9/26/2007

NEW YORK, Sept. 26 /PRNewswire/ -- The world orthopedic biomaterials market, valued at $4 billion in 2006, is projected to accelerate in tandem with the world's aging population, reaching $8.8 billion in 2012, according to Orthopedic Biomaterials: World Market, a new report by Kalorama Information.

Changing demographics -- particularly a world population that is expected to include 2 billion individuals aged 60 or older by 2050, improved longevity, and higher quality-of-life expectations -- are driving the number of musculoskeletal conditions being diagnosed and treated across the globe. In Europe, 15-20% of all primary care consultations are for musculoskeletal conditions. In the United States, one out of every seven Americans reports a musculoskeletal impairment.

BMP (bone morphogenetic proteins) products, the newest and fastest growing segment in the orthopedic biomaterials market, are expected to increase their sales and holdings in the market during the forecasted period, growing by a CAGR of 25% to $2.9 billion and accounting for 39% of the market. Ceramic product sales, which accounted for 25% of the market in 2006, are projected to grow at a steady CAGR of 10% between 2006-2012 but account for only 21% of the orthopedic materials market by 2012.

"As a result of evolving technology, a number of biomaterials have been introduced to the market over the past several years, all of which are biologically active substances intended to extend, enhance, or even replace autologous graft," notes Anne Anscomb, the report's author. "However, it is the most recent innovations in the orthopedic biomaterials, the development of recombinant bone morphogenetic proteins (BMPs) and synthetic ceramic products, which show the greatest promise in the quest for the perfect orthopedic biomaterial."

Orthopedic Biomaterials: World Market focuses on products and markets for bone allografts and bone graft substitutes, which include allograft bone substitutes, ceramic-based, polymer-based, factor-based and hyaluronic acid synovial Fluid substitutes. The report analyzes products in development and on the market, leading competitors, and current issues and trends affecting the industry. This report can be purchased directly from Kalorama Information by visiting: http://www.kaloramainformation.com/Orthopedic-Biomaterials-Edition-1399489.

About Kalorama Information

Kalorama Information publishes the latest independent market research on medical markets, including biotechnology, pharmaceuticals, diagnostics, medical devices, and healthcare sectors. For more information, contact Tom Ehart at 240-747-3014 or tehart@marketresearch.com, or visit http://www.KaloramaInformation.com.

Contact:

Tom Ehart

MarketResearch.com

240-747-3014

tehart@marketresearch.com


'/>"/>
SOURCE Kalorama Information
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Liability issues not seen as roadblock to healthcare technology advancements
2. Governor Doyle Pledges Support for Stem Cell Research and Biotechnology Advancements
3. Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System
4. Using the DCode System to Identify DNA Sequence Variation for Studies of Population Structure in Marine Organisms
5. Differential Gene Expression Analysis of Pure Cell Populations from Frozen UterineTissue Using Laser Capture Microdissection (LCM) and cDNA Microarrays
6. Laser Capture Microdissection of muscle fiber populations and expression analysis by RT-PCR
7. Innovative Tissue Array Technology for High-Throughput Screening of Gene Expression
8. HotMasterAn innovative Hot Start/Cold Stop technology for better PCR* results
9. Enhancing Ruggedness and Full-Scan MS Sensitivity Using Ion Sweep Technology
10. Novel MicroRNA Array Technology for Sensitive miRNA Profiling
11. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
Breaking Biology Technology:
(Date:6/20/2016)... 20, 2016 Securus Technologies, a leading ... for public safety, investigation, corrections and monitoring announced ... it has secured the final acceptance by all ... Managed Access Systems (MAS) installed. Furthermore, Securus will ... be installed by October, 2016. MAS distinguishes between ...
(Date:6/9/2016)... in attendance control systems is proud to announce the introduction of fingerprint attendance control ... right employees are actually signing in, and to even control the opening of doors. ... ... ... Photo - ...
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
Breaking Biology News(10 mins):